| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
D3 Receptor
L-DOPA-2,5,6-d3 does not have a specific pharmacological target distinct from L-DOPA. L-DOPA itself is a precursor to dopamine. It crosses the blood-brain barrier (BBB) and is converted into dopamine in the brain. The deuterated compound is used as an analytical standard or tracer. |
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
L-DOPA-2,5,6-d3 is not pharmacologically active in its own right; it serves as an analytical standard or tracer. It exhibits the same physicochemical properties as native L-DOPA. The compound is used to study the mechanism of action and biological targets of L-DOPA, such as dopamine receptors and the dopaminergic system. L-DOPA-2,5,6-d3 is used in cell culture experiments as a tracer to study the uptake and metabolism of L-DOPA. Cells are treated with the compound, and its conversion to dopamine and other metabolites is monitored. The deuterated compound allows for the tracking of L-DOPA through metabolic pathways. |
| ln Vivo |
In vivo, L-DOPA-2,5,6-d3 is used as a tracer to study the pharmacokinetics and metabolism of L-DOPA. It is administered to animal models, and its distribution and conversion to dopamine are measured. This helps to understand the disposition of L-DOPA and its effects in the brain.
|
| Enzyme Assay |
Cell-free assays using L-DOPA-2,5,6-d3 are not typically performed, as it is used as a tracer. However, it can be used in enzyme assays to study the activity of enzymes involved in L-DOPA metabolism, such as DOPA decarboxylase and COMT. The deuterated compound allows for the differentiation of endogenous and exogenous L-DOPA.
|
| Cell Assay |
Cellular assays using L-DOPA-2,5,6-d3 are conducted using neuronal cell cultures. Cells are treated with the compound, and its uptake and conversion to dopamine are measured by LC-MS/MS. The deuterated tracer enables precise quantification of metabolic flux.
|
| Animal Protocol |
In vivo studies using L-DOPA-2,5,6-d3 are conducted in animal models of Parkinson's disease or other conditions. The compound is administered, and its distribution and metabolism are studied. These studies provide insights into the pharmacokinetics and pharmacodynamics of L-DOPA.
|
| ADME/Pharmacokinetics |
The pharmacokinetics of L-DOPA-2,5,6-d3 are identical to those of native L-DOPA. It is absorbed, distributed, metabolized, and excreted in the same manner. The deuterated compound is used to study these processes in detail.
|
| Toxicity/Toxicokinetics |
L-DOPA-2,5,6-d3 is not a therapeutic agent and toxicity studies are not applicable. It is used in trace amounts as an analytical standard or tracer. Standard laboratory safety practices for handling chemical reference standards should be followed.
|
| References | |
| Additional Infomation |
L-DOPA-2,5,6-d3 is a research compound used to study L-DOPA metabolism, neurotransmitter pathways, and Parkinson's disease. It is available as a high-purity deuterated compound for research purposes. It is not approved for clinical use.
|
| Molecular Formula |
C9H8D3NO4
|
|---|---|
| Molecular Weight |
200.21
|
| Exact Mass |
200.088
|
| CAS # |
53587-29-4
|
| Related CAS # |
L-DOPA;59-92-7
|
| PubChem CID |
6914094
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.49g/cm3
|
| Boiling Point |
448.4ºC at 760 mmHg
|
| Melting Point |
292ºC (dec.)(lit.)
|
| Flash Point |
225ºC
|
| Index of Refraction |
1.654
|
| LogP |
0.752
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
209
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C1=C(C(=C(C(=C1C[C@@H](C(=O)O)N)[2H])O)O)[2H]
|
| InChi Key |
WTDRDQBEARUVNC-UOCCHMHCSA-N
|
| InChi Code |
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1/i1D,2D,4D
|
| Chemical Name |
(2S)-2-amino-3-(2,3,6-trideuterio-4,5-dihydroxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 25 mg/mL (124.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9948 mL | 24.9738 mL | 49.9476 mL | |
| 5 mM | 0.9990 mL | 4.9948 mL | 9.9895 mL | |
| 10 mM | 0.4995 mL | 2.4974 mL | 4.9948 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
